Bini Aikaterini, Ndukwe Michael, Lipede Christina, Vidyadharan Ramesh, Wilson Yvonne, Jester Andrea
Hand and Upper Limb Service, Department of Paediatric Plastic, Hand & Reconstructive Surgery, Birmingham Women's and Children's NHS Foundation Trust, Birmingham B4 6NH, UK.
Burns Centre, Birmingham Women's and Children's NHS Foundation Trust, Birmingham B4 6NH, UK.
J Clin Med. 2025 Aug 1;14(15):5427. doi: 10.3390/jcm14155427.
Biodegradable Temporizing Matrix (BTM) is a new synthetic dermal substitute suitable for wound closure and tissue regeneration. The data in paediatric population remain limited. The study purpose is to review the indications for BTM application in paediatric patients, evaluate the short-term and long-term results, including complications and functional outcomes, as well as to share some unique observations regarding the use of BTM in paediatric population. Patients undergoing reconstructive surgery and BTM application during the last three years were included. Data collected included patient demographics, primary diagnosis, previous surgical management, post-operative complications and final outcomes. BTM was used in 32 patients. The indications varied including epidermolysis bullosa (n = 6), burns (n = 4), trauma (n = 7), infection (n = 4), ischemia or necrosis (n = 11). The results were satisfying with acceptable aesthetic and functional outcomes. Complications included haematoma underneath the BTM leading to BTM removal and re-application (n = 1), BTM infection (n = 1) and split-thickness skin graft failure on top of BTM requiring re-grafting (n = 2). BTM can be a good alternative to large skin grafts, locoregional flaps or even free flaps. The big advantages over other dermal substitutes or skin grafts are that BTM is less prone to infection and offers excellent scarring by preserving the normal skin architecture. Specifically in children, BTM might not require grafting, resulting in spontaneous healing with good scarring. In critically ill patients, BTM reduces the operation time and there is no donor site morbidity. BTM should be considered in the reconstructive ladder when discussing defect coverage options in children and young people.
可生物降解临时基质(BTM)是一种适用于伤口闭合和组织再生的新型合成真皮替代物。儿科人群中的相关数据仍然有限。本研究目的是回顾BTM在儿科患者中的应用指征,评估短期和长期结果,包括并发症和功能结局,并分享一些关于在儿科人群中使用BTM的独特观察结果。纳入了在过去三年中接受重建手术并应用BTM的患者。收集的数据包括患者人口统计学资料、初步诊断、既往手术治疗、术后并发症和最终结局。32例患者使用了BTM。应用指征各不相同,包括大疱性表皮松解症(n = 6)、烧伤(n = 4)、创伤(n = 7)、感染(n = 4)、缺血或坏死(n = 11)。结果令人满意,美学和功能结局均可接受。并发症包括BTM下方血肿导致BTM移除和重新应用(n = 1)、BTM感染(n = 1)以及BTM上方的中厚皮片移植失败需要重新移植(n = 2)。BTM可以是大皮片移植、局部皮瓣甚至游离皮瓣的良好替代物。与其他真皮替代物或皮片相比,其最大优势在于BTM不易感染,并通过保留正常皮肤结构提供出色的瘢痕形成效果。特别是对于儿童,BTM可能无需移植,可实现自发愈合且瘢痕良好。对于危重症患者,BTM可缩短手术时间且无供区并发症。在讨论儿童和青少年的缺损覆盖选择时,在重建阶梯中应考虑BTM。